Bevenopran
From Wikipedia, the free encyclopedia
 |
|
| Systematic (IUPAC) name | |
|---|---|
|
5-[2-Methoxy-4-[[2-(oxan-4-yl)ethylamino]methyl]phenoxy]pyrazine-2-carboxamide
|
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | 676500-67-7 |
| PubChem | CID 10452732 |
| ChemSpider | 8628148 |
| Chemical data | |
| Formula | C20H26N4O4 |
| Molar mass | 386.44484 g/mol |
| 3D model (Jmol) | Interactive image |
|
|
|
|
Bevenopran (INN, USAN) (former developmental code names CB-5945, ADL-5945, MK-2402, OpRA III) is a peripherally selective μ- and δ-opioid receptor antagonist that was under development by Cubist Pharmaceuticals for the treatment of chronic opioid-induced constipation.[1][2][3] It reached phase III clinical trials for this indication before being discontinued.[4][5]
See also[edit]
References[edit]
- ^ Diego L, Atayee R, Helmons P, Hsiao G, von Gunten CF (2011). "Novel opioid antagonists for opioid-induced bowel dysfunction". Expert Opin Investig Drugs. 20 (8): 1047–56. doi:10.1517/13543784.2011.592830. PMID 21663526.
- ^ Siemens W, Gaertner J, Becker G (2015). "Advances in pharmacotherapy for opioid-induced constipation - a systematic review". Expert Opin Pharmacother. 16 (4): 515–32. doi:10.1517/14656566.2015.995625. PMID 25539282.
- ^ Annual Reports in Medicinal Chemistry. Elsevier Science. 13 September 2013. pp. 451–. ISBN 978-0-12-417151-0.
- ^ Combating Opioid-Induced Constipation: New and Emerging Therapies
- ^ Bevenopran
 |
This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |
